Pfizer will be a surefire winner in 2022 as a company regardless of what happens with the COVID-19 pandemic. It already has major supply deals lined up for its COVID-19 vaccine and pill that will generate billions of dollars in revenue. Pfizer's lineup also includes multiple other growth drivers like blood thinner Eliquis and rare heart disease drug Vyndaqel/Vyndamax. $Pfizer(PFE)$

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论